|
|
Insulin Delivery Systems Market Analysis (2008-2012)
|
Zahlen und Fakten zur Studie: | 90 Seiten | |||||||||
| Inhalt der Studie: |
The increasing number of diabetes patients globally is proving a boon for diabetes drugs market. The number of diabetic patients in the world is estimated to reach at more than 250 Million in 2008. Th.....
The increasing number of diabetes patients globally is proving a boon for diabetes drugs market. The number of diabetic patients in the world is estimated to reach at more than 250 Million in 2008. The governments worldwide are taking initiatives on various research and development projects in order to improve drug delivery techniques. This may be beneficial in terms of growing consumer base in developing countries like India and China. The main requirement of present market is to develop efficient delivery methods at low cost and this may change the scenario of the industry. Our recent research study, "Insulin Delivery Systems Market Analysis (2008-2012)”, states that currently the insulin market is characterized by emergence of new drug delivery devices with improved technology and this trend is likely to continue in next few years also. As a result, global insulin market is forecasted to grow at a CAGR of around 15% during 2010-2012. Anticipating the future growth, pharma giants are making investments in active R&D to increase their market share. Our report highlights that the insulin market, driven by the increasing prevalence of diabetes, is presently witnessing robust double-digit growth, thus pushing strong demand for insulin delivery devices. Most of the insulin today is available in injectable form through syringes, pens, pumps and needle-free devices; however, the pain and inconvenience caused by most of these devices are driving pharmaceutical companies to discover other ‘painless’ modes of insulin delivery, particularly oral methods. But, on the other hand, a low cost factor is also playing a major part in success of new drug delivery methods. The report provides extensive information and rational analysis on the global insulin market as well as insulin delivery methods. Thus, it provides valuable information to pharmaceutical and biotech companies and investors looking to enter this market. Analysis and statistics regarding market size, growth, share, regulatory environment and trends in technology development have been thoroughly analyzed in the report to provide clients a comprehensive overview of the market. [Studien Infos ausblenden] |
|||||||||||
|
1. Analyst View 2. Global Diabetes Drug Market 3. Global Insulin Market 3.1 India 3.1.1 Prevalence 3.1.2 Market Analysis 3.2 China 3.2.1 Prevalence 3.2.2 Market Analysis 3.3 US 3.3.1 Prevalence 3.3.2 Market Analysis 3.4 Russia 3.4.1 Prevalence 3.4.2 Market Analysis 3.5 Japan 3.5.1 Prevalence 3.5.2 Market Analysis 3.6 Germany 3.6.1 Prevalence 3.6.2 Market Analysis 3.7 Pakistan 3.7.1 Prevalence 3.7.2 Market Analysis 3.8 Brazil 3.8.1 Prevalence 3.8.2 Market Analysis 3.9 Mexico 3.9.1 Prevalence 3.10 Egypt 3.10.1 Prevalence 4. Insulin Delivery Devices 4.1 Present Devices 4.1.1 Insulin Pens 4.1.1.1 Mechanism and Technologies 4.1.1.2 Market Analysis 4.1.1.2.1 Global 4.1.1.2.2 US 4.1.1.2.3 Europe 4.1.1.2.4 Japan 4.1.1.3 Pros and Cons 4.1.1.4 Key Players 4.1.2 Insulin Pumps 4.1.2.1 Mechanism and Technologies 4.1.2.2 Market Analysis 4.1.2.2.1 Global 4.1.2.2.2 US 4.1.2.2.3 Non US 4.1.2.3 Pros and Cons 4.1.2.4 Key Players 4.1.3 Insulin Syringes 4.1.3.1 Mechanism and Technology 4.1.3.2 Market Analysis 4.1.3.3 Pros and Cons 4.1.3.4 Future Outlook (2010-2012) 4.1.4 Insulin Jet Injectors 4.1.4.1 Mechanism and Technologies 4.1.4.2 Market Analysis 4.1.4.3 Pros and Cons 4.1.4.4 Future Outlook (2010-2012) 4.2 Future Devices 4.2.1 Oral Insulin 4.2.2 Insulin Patch 4.2.3 Implantable Insulin Pumps 5. Key Market Trends and Restraints 5.1 Convenient and Less Painful Modes of Insulin Delivery 5.2 Improved Access and Lower Insulin Prices in the Developing World 5.3 US and Developing Countries - Potential Markets for Insulin Syringes 5.4 High R&D and Production Cost 5.5 Insurance Reimbursement 6. Key Players 6.1 Eli Lilly & Company 6.2 Novo Nordisk A/S 6.3 Sanofi-Aventis 6.4 Becton, Dickinson and Company 6.5 Medtronic, Inc. [Inhaltsverzeichnis ausblenden] |
||||||||||||
|
Table 2-1: Global - List of Top Anti-diabetic Brands (2008) Table 3-1: India - Diabetic Patients in Age Group 20-79 Years (‘000), 2007 Table 3-2: India - Forecast for Diabetic Patients in Age Group 20-79 Years (‘000), 2025 Table 3-3: China - Diabetic Patients in Age Group 20-79 Years ('000), 2007 Table 3-4: China - Forecast for Diabetic Patients in Age Group 20-79 Years ('000), 2025 Table 3-5: US - Diabetic Patients in Age Group 20-79 Years ('000), 2007 Table 3-6: US - Forecast for Diabetic Patients in Age Group 20-79 Years ('000), 2025 Table 3-7: Russia - Diabetic Patients in Age Group 20-79 Years ('000), 2007 Table 3-8: Russia - Forecast for Diabetic Patients in Age Group 20-79 Years ('000), 2025 Table 3-9: Japan - Diabetic Patients in Age Group 20-79 Years ('000), 2007 Table 3-10: Japan - Forecast for Diabetic Patients in Age Group 20-79 Years ('000), 2025 Table 3-11: Germany - Diabetic Patients in Age Group 20-79 Years ('000), 2007 Table 3-12: Germany - Forecast for Diabetic Patients in Age Group 20-79 Years ('000), 2025 Table 3-13: Pakistan - Diabetic Patients in Age Group 20-79 Years ('000), 2007 Table 3-14: Pakistan - Forecast for Diabetic Patients in Age Group 20-79 Years ('000), 2025 Table 3-15: Brazil - Diabetic Patients in Age Group 20-79 Years ('000), 2007 Table 3-16: Brazil - Forecast for Diabetic Patients in Age Group 20-79 Years ('000), 2025 Table 3-17: Mexico - Diabetic Patients in Age Group 20-79 Years ('000), 2007 Table 3-18: Mexico - Forecast for Diabetic Patients in Age Group 20-79 Years ('000), 2025 Table 3-19: Egypt - Diabetic Patients in Age Group 20-79 Years (‘000), 2007 Table 3-20: Egypt - Forecast for Diabetic Patients in Age Group 20-79 Years ('000), 2025 Figure 2-1: Global - Number of Diabetic Patients (Million), 2007 & 2025 Figure 2-2: Global - Diabetes Drugs Market (Billion US$), 2007-2009 Figure 2-3: US - Top 5 Anti-diabetic Drugs (Billion Euro) Figure 2-4: EU - Top 5 Anti-diabetic Drugs (Million Euro) Figure 3-1: Global - Insulin Market (Billion US$), 2007-2009 Figure 3-2: Global - Forecast for Insulin Market (Billion US$), 2010-2012 Figure 3-3: Global - Insulin Demand (Kg), 2006 & 2012 Figure 3-4: India - Number of Diabetic Patients (Million), 2008 & 2030 Figure 3-5: India - Insulin Market (Million US$), 2007-2009 Figure 3-6: India - Share of Key Players in Insulin Market (2008) Figure 3-7: China - Insulin Market (Million US$), 2007-2009 Figure 3-8: China - Share of Key Players in Insulin Market (Q4 2008) Figure 3-9: US - Share of Key Players in Insulin Market (2008) Figure 3-10: Russia - Insulin Market (Million US$), 2007-2009 Figure 3-11: Russia - Share of Key Players in Insulin Market (H1 2006) Figure 3-12: Russia - Insulin Market by Channel of Sales (%), 2007 Figure 3-13: Japan - Insulin Market (Billion JPY), 2007-2009 Figure 3-14: Japan - Share of Novo Nordisk in Insulin Market (2008) Figure 3-15: Germany - Insulin Market (Billion US$), 2007-2009 Figure 3-16: Brazil - Insulin Market (Million BRL), 2007-2009 Figure 4-1: Global, US, Europe & Japan - Insulin Units Delivered through Pen Devices (%), 2006 Figure 4-2: US - Insulin Pen Devices Market (Million US$), 2007-2009 Figure 4-3: US - Forecast for Insulin Pen Devices Market (Million US$), 2010-2012 Figure 4-4: US - Insulin Units Delivered through Pen Devices (%), 2004 & 2006-2008 Figure 4-5: US - Share of Disposable and Refillable Pen Devices (2006) Figure 4-6: Europe - Insulin Units Delivered through Pen Devices (%), 2004, 2006-2008 Figure 4-7: Europe - Share of Disposable and Refillable Pen Devices (2006) Figure 4-8: Japan - Insulin Units Delivered through Pen Devices (%), 2004 & 2006-2008 Figure 4-9: Global - Share of Key Players in Pen Devices Market (2005) Figure 4-10: Global - Insulin Pumps and Disposables Market (Million US$), 2007-2009 Figure 4-11: Global - Forecast for Insulin Pumps and Disposables Market (Million US$), 2010-2012 Figure 4-12: Global - Share of US and Non US in Insulin Pumps and Disposables Market (2008) Figure 4-13: Global - Forecast for Share of US and Non US in Insulin Pumps and Disposables Market (2012) Figure 4-14: US - Insulin Pumps and Disposables Market (Million US$), 2007-2009 Figure 4-15: US - Forecast for Insulin Pumps and Disposables Market (Million US$), 2010-2012 Figure 4-16: US - Insulin Pump Sales (‘000 Units), 2004, 2008 & 2012 Figure 4-17: Non US - Insulin Pumps and Disposables Market (Million US$), 2007-2009 Figure 4-18: Non US - Forecast for Insulin Pumps and Disposables Market (Million US$), 2010-2012 Figure 4-19: Global - Share of Key Players in Insulin Pumps Market (2008) Figure 4-20: US - Share of Key Players in Insulin Pumps Market (2008) Figure 4-21: Europe - Share of Key Players in Insulin Pumps Market (2008) Figure 4-22: Japan - Share of Nipro in Insulin Pumps Market (2005) Figure 4-23: US - Insulin Syringes Market (Million US$), 2007-2009 Figure 4-24: US - Share of Insulin Syringes Market (2005 & 2007-2009) Figure 4-25: US - Forecast for Insulin Syringes Market (Million US$), 2010-2012 Figure 4-26: US - Forecast for Share of Insulin Syringes Market (2010-2012) Figure 4-27: Global - Insulin-driven Jet Injectors Market (Million US$), 2007-2009 Figure 4-28: US - Insulin-driven Jet Injectors Market (Million US$), 2007-2009 Figure 4-29: US - Share of Insulin-driven Jet Injectors Market (2007-2009) Figure 4-30: Global - Forecast for Insulin-driven Jet Injectors Market (Million US$), 2010-2012 Figure 4-31: US - Forecast for Insulin-driven Jet Injectors Market (Million US$), 2010-2012 Figure 4-32: US - Forecast for Share of Insulin-driven Jet Injectors Market (2010-2012) [Tabellenverzeichnis ausblenden] |
||||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
|||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||


